NCT05865301Recruiting
Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy
Source: ClinicalTrials.gov · Last updated 4 Jun 2026
Brief summary (registry, in English)
To use a consistent and standardized platform to retrospectively and prospectively study children and young adults with B cell malignancies receiving Immunotherapy, blinatumomab and/or inotuzumab ozogamicin.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 1 May 2023
- Start date
- 29 Jun 2023
- Primary completion date
- Apr 2027
- Lead sponsor
- Stanford University
- Diseases
- Childhood cancers
- NCT number
- NCT05865301
What you commit to
- Study type: Observational
- Planned participants: 500
- From 29 Jun 2023 to the primary completion date, Apr 2027
- 22 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- \* Disease Status - B cell precursor acute lymphoblastic leukemia (ALL) or B cell lymphoma
- Who either:
- Experienced refractory or relapsed disease, treated with standard chemotherapy, without immunotherapy treatment.
- OR
- Previously undergone standard of care immunotherapy with FDA approved therapies, such as Kymriah™ (CTL019, tisagenlecleucel), blinatumomab or
- Age: Greater than or equal to 0 year of age and less than or equal to 26 years of age.
- Disease Status - B cell precursor acute lymphoblastic leukemia (ALL) or B cell lymphoma
- Age: Greater than or equal to 0 year of age and less than or equal to 26 years of age
- Patients who are either:
- Undergoing evaluation for leukapheresis for planned standard of care tisagenlecleucel therapy, or planned for therapy with blinatumomab or inotuzumab. (Patients who received prior tisagenlecleucel, blinatumomab or inotuzumab on an established clinical trial and are now scheduled for commercial CAR, blinatumomab or inotuzumab therapy are also eligible) Or
- Experienced refractory or relapsed B cell precursor acute lymphoblastic leukemia (ALL) or B cell lymphoma
- Ability to give informed consent. All subjects ≥ 18 years of age must be able to give informed consent or have legal authorized representative (LAR) (i.e. parent or guardian) to consent, if not in capacity to give consent independently. For subjects \<18 years old their LAR must give informed consent. Pediatric subjects will be included in age appropriate discussion and written assent will be obtained for those \> 7 years of age, when appropriate, according to institutional procedures.
Age in the registry: - to 26 years · Sex: All · Does not accept healthy volunteers
Sites (22)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Johns Hopkins University/Sidney Kimmel Cancer Center Coordinator of this site? Confirm its status | Baltimore | United States | Recruiting |
| Dana-Farber Cancer Institute Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
| Atrium Health Levine Cancer Institute Coordinator of this site? Confirm its status | Charlotte | United States | Recruiting |
| Ann & Robert H. Lurie Children's Hospital of Chicago Coordinator of this site? Confirm its status | Chicago | United States | Recruiting |
| Cincinnati Children's Hospital Medical Center Coordinator of this site? Confirm its status | Cincinnati | United States | Recruiting |
| UT Southwestern/Simmons Cancer Center-Dallas Coordinator of this site? Confirm its status | Dallas | United States | Recruiting |
| City of Hope Comprehensive Cancer Center Coordinator of this site? Confirm its status | Duarte | United States | Recruiting |
| Saint Jude Children's Research Hospital Coordinator of this site? Confirm its status | Fairfax | United States | Recruiting |
| Cook Children's Medical Center Coordinator of this site? Confirm its status | Fort Worth | United States | Recruiting |
| University of Florida Health Science Center - Gainesville Coordinator of this site? Confirm its status | Gainesville | United States | Recruiting |
| Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital Coordinator of this site? Confirm its status | Grand Rapids | United States | Recruiting |
| Medical College of Wisconsin Coordinator of this site? Confirm its status | Milwaukee | United States | Recruiting |
| Nemours Children's Hospital Coordinator of this site? Confirm its status | New Castle | United States | Recruiting |
| Stanford University Coordinator of this site? Confirm its status | Palo Alto | United States | Recruiting |
| Children's Hospital of Pittsburgh of UPMC Coordinator of this site? Confirm its status | Pittsburgh | United States | Recruiting |
| OHSU Knight Cancer Institute Coordinator of this site? Confirm its status | Portland | United States | Recruiting |
| UCSF (Benioff Children's) Coordinator of this site? Confirm its status | San Francisco | United States | Recruiting |
| Seattle Children's Hospital Coordinator of this site? Confirm its status | Seattle | United States | Recruiting |
| St. Louis Children's (Washington University) Coordinator of this site? Confirm its status | St Louis | United States | Recruiting |
| Johns Hopkins All Children's Hospital Coordinator of this site? Confirm its status | St. Petersburg | United States | Recruiting |
| Children's Hospital at Montefiore Coordinator of this site? Confirm its status | The Bronx | United States | Recruiting |
| Banner University Medical Center - Tucson Coordinator of this site? Confirm its status | Tucson | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.